Quanterix Returns To Quarterly Sales Growth — But Revenue Still Falls 13% From Last Year

Lower expenses narrowed the net loss, while Quanterix tightened its annual sales outlook and expanded Alzheimer’s testing partnerships.

Share
Quanterix Returns To Quarterly Sales Growth — But Revenue Still Falls 13% From Last Year

Quanterix, which makes tools for measuring proteins in blood and tissue, increased third-quarter sales 6.3% from the previous quarter to $35.0 million, but revenue remained 13% below a year earlier. The unaudited results, released Monday with an SEC filing, showed a smaller net loss as selling and administrative spending and impairment and restructuring costs fell.

The Recovery Has Limits

Service and other revenue fell to $9.4 million from $14.0 million a year earlier; product sales slipped to $25.2 million from $26.2 million. On the company’s comparison adjusted for Akoya’s pre-acquisition sales and a terminated diagnostics development program, total revenue declined 9%, rather than the reported 13%, according to its earnings presentation.

The improvement from the second quarter included higher spatial-biology sales, which Quanterix attributed to consumables revenue approaching a record. Simoa sales increased a few percent on instrument strength. Americas revenue grew close to 20% from the previous quarter, while Europe, the Middle East and Africa declined, which the company attributed to seasonality.

Everett Cunningham, Quanterix’s president and CEO, called the rebound a “first step in restoring growth.” He said reorganizing the commercial teams and adding leadership “should accelerate our execution in the fourth quarter and beyond.”

Lower Costs Narrow The Loss

The net loss narrowed 35.6% to $21.6 million, or $0.46 a share, from $33.5 million, or $0.73 a share. Operating expenses dropped to $36.0 million from $53.2 million: selling and administrative costs fell to $28.5 million from $38.0 million, and impairment and restructuring charges fell to $171,000 from $7.2 million.

The adjusted picture was less favorable. The loss before interest, taxes, depreciation and amortization, with additional company adjustments, widened to $12.2 million from $11.9 million. Gross margin under standard accounting fell 0.9 percentage points to 38.6%, while adjusted gross margin rose 1.5 percentage points to 47.4%.

Quanterix narrowed its annual revenue forecast to $142–146 million and kept its adjusted gross-margin outlook at 48–50%. Management expects approximately $70 million in cash at year-end and no debt. The quarter ended with $80.7 million in cash, cash equivalents, marketable securities and restricted cash; operations used $39.4 million during the first nine months, compared with $60.8 million a year earlier.

Building The Alzheimer’s Testing Business

Quanterix sells instruments, kits and software to research laboratories and drug companies, then earns recurring revenue from consumables, warranties and service contracts. Its Accelerator Laboratory in Bedford, Massachusetts, also provides research services and clinical testing, including blood tests used to evaluate Alzheimer’s disease and other neurological conditions.

LucentAD test volume doubled as partnerships expanded. New relationships with New York’s Sherman Abrams Lab and Mississippi’s TruPath are underway. In Florida, coverage for qualifying blood-biomarker tests, including LucentAD Complete, began November 1, 2026, for traditional Medicaid members and state employees who meet medical-necessity criteria.

The diagnostics expansion follows Jim Gute’s appointment as chief commercial officer in mid-August and Dr. Yuri Fesko’s appointment as chief medical officer in September. Chinese regulatory approvals now cover HD-X and SR-X instruments and kits for four neurological biomarkers, with Innovita Biological Technology working to broaden access there.

Quanterix also expanded its Simoa assay menu. Its PhenoCode 2.0 Molecular Barcoding Kit is commercially available, and the Accelerator Lab is accepting requests for custom tissue-analysis panels for antibody–drug conjugates.

Quanterix expects its TIME and ADC tissue-analysis panels to ship in early 2027. It also plans a 2027 regulatory submission for the HD-X diagnostic instrument.

Sources